BR112015001608A2 - inibidor lfa-1 e polimorfo do mesmo - Google Patents

inibidor lfa-1 e polimorfo do mesmo

Info

Publication number
BR112015001608A2
BR112015001608A2 BR112015001608A BR112015001608A BR112015001608A2 BR 112015001608 A2 BR112015001608 A2 BR 112015001608A2 BR 112015001608 A BR112015001608 A BR 112015001608A BR 112015001608 A BR112015001608 A BR 112015001608A BR 112015001608 A2 BR112015001608 A2 BR 112015001608A2
Authority
BR
Brazil
Prior art keywords
polymorph
inhibitor
lfa
alpha
disclosed
Prior art date
Application number
BR112015001608A
Other languages
English (en)
Other versions
BR112015001608B1 (pt
Inventor
C A Brot Elisabeth
Robert Zeller James
Hall Michael
Venkatraman Sripathy
Iyer Subashree
Original Assignee
Sarcode Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49995472&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015001608(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sarcode Bioscience Inc filed Critical Sarcode Bioscience Inc
Publication of BR112015001608A2 publication Critical patent/BR112015001608A2/pt
Publication of BR112015001608B1 publication Critical patent/BR112015001608B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

resumo “inibidor lfa-1 e polimorfo do mesmo” método de preparação e purificação de um composto de fórmula i, interme-diários do mesmo, um polimorfo do mesmo, e compostos relacionados são revela-dos. formulações e usos dos mesmos no tratamento de doenças mediadas por lfa-1 também são revelados.
BR112015001608-1A 2012-07-25 2013-07-25 Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1 BR112015001608B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261675663P 2012-07-25 2012-07-25
US61/675.663 2012-07-25
US201261680099P 2012-08-06 2012-08-06
US61/680.099 2012-08-06
US201261729294P 2012-11-21 2012-11-21
US61/729.294 2012-11-21
PCT/US2013/052044 WO2014018748A1 (en) 2012-07-25 2013-07-25 Lfa-1 inhibitor and polymorph thereof

Publications (2)

Publication Number Publication Date
BR112015001608A2 true BR112015001608A2 (pt) 2017-07-04
BR112015001608B1 BR112015001608B1 (pt) 2022-08-23

Family

ID=49995472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001608-1A BR112015001608B1 (pt) 2012-07-25 2013-07-25 Métodos para purificação e síntese de um composto inibidor lfa-1, mistura reacional e composições compreendendo o dito composto e composto isolado inibidor lfa-1

Country Status (13)

Country Link
US (4) US9085553B2 (pt)
EP (2) EP2877465A4 (pt)
JP (3) JP6607780B2 (pt)
KR (2) KR102157608B1 (pt)
CN (2) CN110922393A (pt)
AU (5) AU2013295706A1 (pt)
BR (1) BR112015001608B1 (pt)
CA (1) CA2879982C (pt)
HK (2) HK1210145A1 (pt)
IN (1) IN2015DN00847A (pt)
MX (2) MX2015001098A (pt)
RU (1) RU2658015C2 (pt)
WO (1) WO2014018748A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102617557A (zh) * 2005-05-17 2012-08-01 萨可德生物科学公司 治疗眼病的组合物和方法
US20090258070A1 (en) * 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
BR112017005856A2 (pt) 2014-09-25 2017-12-19 Sarcode Bioscience Inc reação de carboxilação de fluxo contínuo
JP2018510668A (ja) 2015-01-12 2018-04-19 ケダリオン セラピューティックス，インコーポレイテッド 微小液滴の繰り出し装置及び方法
CA3016546A1 (en) 2016-03-04 2017-09-08 James M. Rynerson Method of treating an eye disorder by inhibiting or disrupting bacterial biofilm formation
EP3492466B1 (en) * 2016-07-29 2022-06-01 Wuhan LL Science And Technology Development Co., Ltd. Oral solid preparation and use thereof
JP2019531334A (ja) 2016-08-12 2019-10-31 シルク テクノロジーズ、リミテッド 炎症を治療するための絹由来タンパク質
CN108084067B (zh) * 2016-11-22 2019-08-30 重庆圣华曦药业股份有限公司 一种立他司特中间体的制备方法
CN106947792A (zh) * 2017-03-07 2017-07-14 上海倍殊生物科技有限公司 一种间甲砜基‑l‑苯丙氨酸的制备方法
CA3068522A1 (en) 2017-06-30 2019-01-03 Scinopharm Taiwan, Ltd. Process for preparing lifitegrast and intermediates thereof
US10723721B2 (en) * 2017-07-24 2020-07-28 Interquim, S.A. Process for preparing and purifying the LFA-1 antagonist lifitegrast
US20200369652A1 (en) * 2017-08-03 2020-11-26 Dr. Reddy's Laboratories Limited Processes for preparation of lifitegrast and intermediates thereof
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
US11246862B2 (en) 2017-10-10 2022-02-15 Mankind Pharma Ltd. Process for the preparation of lifitegrast
WO2019097547A1 (en) 2017-11-15 2019-05-23 Cipla Limited An improved process for the preparation of lifitegrast or salts thereof
US11001574B2 (en) 2017-11-17 2021-05-11 Medichem S.A. Process to obtain a tetrahydroisoquinoline derivative
KR20200105657A (ko) 2018-01-15 2020-09-08 코그니보티스 에이비 산업용 로봇 아암
US10435395B1 (en) 2018-03-30 2019-10-08 Scinopharm Taiwan, Ltd. Crystal forms of lifitegrast
US11345683B2 (en) * 2018-03-31 2022-05-31 Aurobindo Pharma Ltd Process for the preparation of lifitegrast
IT201800006337A1 (it) * 2018-06-14 2019-12-14 Procedimento per la preparazione di lifitegrast
CN111100118A (zh) * 2018-10-29 2020-05-05 重庆圣华曦药业股份有限公司 一种立他司特杂质及其制备方法
CN109384717A (zh) * 2018-10-29 2019-02-26 广安凯特制药有限公司 5,7-二氯-1,2,3,4-四氢异喹啉-6-甲酸盐酸盐水合物及其制备方法和用途
CN111285855A (zh) * 2018-12-07 2020-06-16 苏州旺山旺水生物医药有限公司 一种制备化合物Lifitegrast的方法
CN111471003B (zh) * 2019-01-24 2022-09-23 上海皓元医药股份有限公司 一种立他司特中间体的制备方法
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
CN114025759A (zh) * 2019-04-18 2022-02-08 阿祖拉眼科有限公司 用于治疗眼病的化合物和方法
CN110256343A (zh) * 2019-05-28 2019-09-20 苏州芝宇生物科技有限公司 3,5-二氯-4-溴异喹啉衍生物及其制备方法和应用
CN112409256B (zh) * 2019-08-21 2024-04-02 山东福长药业有限公司 5,7-二氯四氢异喹啉缩醛胺类化合物、其制备方法与应用
CN111057003A (zh) * 2019-12-06 2020-04-24 广安凯特制药有限公司 一种立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉的合成方法
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
EP4120974A1 (en) 2020-04-17 2023-01-25 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system
CN111205275A (zh) * 2020-04-22 2020-05-29 南京佰麦生物技术有限公司 立他司特晶型及其制备方法
CN112321506B (zh) * 2020-11-26 2021-12-24 江西天戌药业有限公司 一种5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
CN112500343B (zh) * 2020-12-26 2023-04-07 山东金城柯瑞化学有限公司 5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法
CN112300139A (zh) * 2020-12-29 2021-02-02 南京佰麦生物技术有限公司 立他司特水合物晶型及其制备方法
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
CN113880819A (zh) * 2021-09-18 2022-01-04 浙江大学医学院附属第一医院 立他司特的制备方法及其中间体化合物
CN114524767B (zh) * 2022-03-11 2022-10-18 成都道合尔医药技术有限公司 立他司特中间体5,7-二氯-1,2,3,4-四氢异喹啉盐酸盐的合成方法
CN115784950A (zh) * 2022-12-08 2023-03-14 广东先强药业有限公司 一种立他司特中间体的制备方法
CN116239532B (zh) * 2022-12-19 2023-11-07 浙江博崤生物制药有限公司 一种二氯四氢异喹啉羧酸的中间体及其制备方法和应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5759843A (en) * 1980-09-30 1982-04-10 Neos Co Ltd Perfluoroalkyl ether amide derivative and its preparation
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3852374T2 (de) 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5236704A (en) 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
DE3802996A1 (de) 1988-02-02 1989-08-10 Cassella Ag Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen
US5424399A (en) 1988-06-28 1995-06-13 The Children's Medical Center Corporation Human CR3α/β heterodimers
ES2075016T3 (es) 1988-08-23 1995-10-01 Dana Farber Cancer Inst Inc La subunidad alfa del receptor de adherencia a leucocitos lfa-1.
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
KR900701846A (ko) 1988-09-28 1990-12-04 원본미기재 세포간 점착분자 및 이의 결합 리간드
US5149780A (en) 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
CA2050329A1 (en) 1989-03-09 1990-09-10 Timothy A. Springer Method of treating viral infections using lfa-1
AU5553290A (en) 1989-04-28 1990-11-29 Baylor College Of Medicine Dissemination of hiv-1 infected cells
CH679207A5 (pt) 1989-07-28 1992-01-15 Debiopharm Sa
WO1991019511A1 (en) 1990-06-18 1991-12-26 The General Hospital Corporation CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5318965A (en) 1990-08-24 1994-06-07 Abbott Laboratories Quinobenzoxazine, antineoplastic agents
AU8631991A (en) 1990-08-27 1992-03-17 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
JP2995860B2 (ja) 1990-11-27 1999-12-27 味の素株式会社 新規ペプチド
US5288854A (en) 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE69229275T2 (de) 1991-10-04 1999-12-30 Us Health Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5298492A (en) 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
WO1994011400A1 (en) 1992-11-18 1994-05-26 Helsinki University Licensing Ltd. Oy Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis
CA2150574A1 (en) 1993-01-06 1994-07-21 Shalaby W. Shalaby Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5424289A (en) 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5397791A (en) 1993-08-09 1995-03-14 Merck & Co., Inc. Fibrinogen receptor antagonists
PT656348E (pt) 1993-12-03 2000-10-31 Hoffmann La Roche Derivados do acido acetico como medicamentos
US5470953A (en) 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
EP0762886A4 (en) 1994-04-19 1999-03-31 Univ Kansas ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US5510495A (en) * 1994-09-19 1996-04-23 The Du Pont Merck Pharmaceutical Company Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis
US5585359A (en) 1994-09-29 1996-12-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE170179T1 (de) 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
CA2250981C (en) 1996-04-23 2002-07-02 Kinerton Limited Acidic polylactic polymers
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2270475T3 (es) 1996-11-27 2007-04-01 Bristol-Myers Squibb Pharma Company Nuevos antagonistas de receptores de integrina.
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
AR012443A1 (es) 1997-04-16 2000-10-18 Uriach & Cia Sa J Nuevas carboxamidas como inhibidores de la agregacion plaquetaria, procedimiento para su preparacion, composiciones farmaceuticas que loscontienen y uso de los mismos en la manufactura de medicamentos
WO1999049856A2 (en) 1998-03-27 1999-10-07 Genentech, Inc. Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US7097851B1 (en) 1998-11-27 2006-08-29 Kanji Takada Oral formulation for gastrointestinal drug delivery
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6773916B1 (en) 1999-01-05 2004-08-10 The Flinders University Of South Australia Agents and methods for treatment and diagnosis of ocular disorders
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
CZ300551B6 (cs) 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
AU1186401A (en) 1999-06-23 2001-01-22 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
KR20020031407A (ko) 1999-08-18 2002-05-01 다푸르 가브리에 펩타이드의 서방형 제제
ECSP003707A (es) 1999-10-13 2002-05-23 Novartis Ag Diazepanes
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
EP1237575B1 (en) 1999-12-14 2008-08-06 Genentech, Inc. Tnf-alpha antagonist and lfa-1 antagonist for treating rheumatoid arthritis
US7521061B2 (en) 1999-12-31 2009-04-21 Rutgers, The State University Of New Jersey Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
AU775905B2 (en) 1999-12-31 2004-08-19 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
JP2003519164A (ja) 1999-12-31 2003-06-17 ルトガーズ、ザ ステイト ユニバーシティ ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤
US20030064105A1 (en) 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
US6515124B2 (en) 2000-02-09 2003-02-04 Hoffman-La Roche Inc. Dehydroamino acids
AU6038601A (en) 2000-05-05 2001-11-20 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Amino acid derivatives and their use as medicines
GB0011817D0 (en) 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
CA2414461A1 (en) 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JP2002030052A (ja) * 2000-07-18 2002-01-29 Tosoh Corp ヒドロキシアミノカルボン酸、その用途、及びその製造法
RU2003112232A (ru) * 2000-09-27 2004-09-20 Асахи Гласс Компани, Лимитед (Jp) Способ получения ацилфторида и соли карбоновой кислоты
PE20020420A1 (es) 2000-10-02 2002-06-27 Novartis Ag Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
GB0028367D0 (en) 2000-11-21 2001-01-03 Celltech Chiroscience Ltd Chemical compounds
CA2429353A1 (en) 2000-11-28 2002-08-01 Genentech, Inc. Lfa-1 antagonist compounds
WO2002050080A1 (en) 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
CA2435415A1 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
EP1231212B1 (en) 2001-02-06 2006-12-20 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
US20030068320A1 (en) 2001-03-02 2003-04-10 Christine Dingivan Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP1383376A4 (en) 2001-03-19 2006-03-08 Praecis Pharm Inc PHARMACEUTICAL FORMULATIONS WITH PROLONGED RELEASE
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
JP4583751B2 (ja) 2001-06-06 2010-11-17 アベンティス・フアーマ・リミテッド 炎症性疾患の治療に使用するための置換されたテトラヒドロイソキノリン
JP2005519884A (ja) 2001-12-19 2005-07-07 アルザ・コーポレーシヨン 親水性高分子の経口生利用度を向上させる調合物および投薬形態物
AU2003224649B2 (en) 2002-03-04 2006-09-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Sustained release drug formulations containing a carrier peptide
CN1684738A (zh) 2002-09-20 2005-10-19 爱尔康公司 细胞因子合成抑制剂用于治疗干眼病的用途
US7785578B2 (en) 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
RU2005117343A (ru) * 2002-12-20 2006-01-27 Астразенека Аб (Se) Новые производные пиперидина в качестве модуляторов хемокинового рецептора ccr5
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005042710A1 (en) 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
GT200500139A (es) 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
CN101166736B (zh) 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
CN102617557A (zh) 2005-05-17 2012-08-01 萨可德生物科学公司 治疗眼病的组合物和方法
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
JP4193895B2 (ja) 2006-10-12 2008-12-10 横河電機株式会社 欠陥検査装置
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
NZ586900A (en) 2008-01-01 2012-10-26 Cipla Ltd Anhydrous polymorphic form b of bosentan and uses thereof
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) * 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2014018748A1 (en) * 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Also Published As

Publication number Publication date
US20140031387A1 (en) 2014-01-30
AU2017265071B2 (en) 2019-08-22
EP3715345A3 (en) 2020-11-11
HK1210782A1 (en) 2016-05-06
EP2877465A1 (en) 2015-06-03
KR20150067129A (ko) 2015-06-17
US9708303B2 (en) 2017-07-18
RU2015102926A (ru) 2016-09-20
EP2877465A4 (en) 2016-05-11
US9085553B2 (en) 2015-07-21
HK1210145A1 (en) 2016-04-15
JP2018162313A (ja) 2018-10-18
CA2879982C (en) 2020-09-01
JP2020128433A (ja) 2020-08-27
US20190382389A1 (en) 2019-12-19
CN104797574B (zh) 2019-11-22
JP7008750B2 (ja) 2022-01-25
AU2019210525B2 (en) 2020-12-17
MX2020001602A (es) 2020-07-13
AU2019210525A1 (en) 2019-08-15
EP3715345B1 (en) 2024-04-10
CA2879982A1 (en) 2014-01-30
JP2015523398A (ja) 2015-08-13
RU2018121523A (ru) 2019-12-13
JP6607780B2 (ja) 2019-11-20
RU2658015C2 (ru) 2018-06-19
BR112015001608B1 (pt) 2022-08-23
IN2015DN00847A (pt) 2015-06-12
AU2023204287A1 (en) 2023-07-27
US10906892B2 (en) 2021-02-02
RU2018121523A3 (pt) 2022-02-25
CN104797574A (zh) 2015-07-22
CN110922393A (zh) 2020-03-27
EP3715345A2 (en) 2020-09-30
KR102157608B1 (ko) 2020-09-18
AU2020281063A1 (en) 2021-01-07
US10214517B2 (en) 2019-02-26
WO2014018748A1 (en) 2014-01-30
US20180118726A1 (en) 2018-05-03
AU2017265071A1 (en) 2017-12-14
US20150336939A1 (en) 2015-11-26
MX2015001098A (es) 2015-09-25
AU2013295706A1 (en) 2015-02-19
KR20200108932A (ko) 2020-09-21

Similar Documents

Publication Publication Date Title
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
NZ703064A (en) Inhibitors of hepatitis c virus
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
BR112014001801A2 (pt) indazóis
PH12015500260A1 (en) Neprilysin inhibitors
IN2014KN00948A (pt)
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
BR112014031731A2 (pt) entidades químicas, composições farmacêuticas, usos de entidades químicas ou de composições, compostos ou sais farmaceuticamente aceitáveis dos mesmos e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática pde1 e para modular a atividade da enzima pde1
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
IN2012DN00971A (pt)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
BR112015006436A2 (pt) novas piridinonas bicíclicas
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201300946A1 (ru) Асимметричные мочевины и их медицинское применение
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
MY191352A (en) Aldosterone synthase inhibitors
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2013, OBSERVADAS AS CONDICOES LEGAIS